Crossmark

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries

Crossref DOI link: https://doi.org/10.1016/j.reuma.2023.02.005

Published Print: 2023-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Reyes, J.M. http://orcid.org/0000-0003-0806-7173
Gutierrez, M.V. http://orcid.org/0000-0001-6455-8685
Madariaga, H.

Otero, W.

Guzman, R.

Izquierdo, J.

Abello, M.

Velez, P.

Castillo, D.

Ponce de Leon, D. http://orcid.org/0000-0003-2250-6849
Lukic, T.

Amador, L.
Funding

Funding for this research was provided by:

Pfizer
License Information

Text and Data Mining valid from 2023-06-01

Text and Data Mining valid from 2023-06-01

Version of Record valid from 2023-03-15
More Information

This article is maintained by: Elsevier

Article Title: Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries

Journal Title: Reumatología Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reuma.2023.02.005

Content Type: article

Copyright: © 2023 The Authors. Published by Elsevier España, S.L.U.